Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Twist BioscienceMIL:1TWST +0.64%47 Days Payable is 25.84 as of Jun. 2026, which is 41% below its 10-year median of 44.01. GuruFocus rates MIL:1TWST with a GF Score™ of 47/100 and a GF Value™ of €46.60 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Twist Bioscience ranks worse than 85.26% on this metric.
The historical rank and industry rank for Twist Bioscience's Days Payable or its related term are showing as below:
MIL:1TWST'
s Days Payable Range Over the Past 10 Years
Min: 12.51 Med: 44.01 Max: 90.54
Current: 23.69
During the past 10 years, Twist Bioscience's highest Days Payable was 90.54. The lowest was 12.51. And the median was 44.01.
MIL:1TWST's Days Payable is ranked worse than 85.26% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.945
vs MIL:1TWST: 23.69
Twist Bioscience's Days Payable
increased
from Jun. 2025 (20.98) to Jun. 2026 (25.84).
It may suggest that Twist Biosciencedelayed paying its suppliers.
The historical data trend for Twist Bioscience's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1TWST vs BLLN, SHC, RDNT: Days Payable Comparison
For the Diagnostics & Research subindustry, Twist Bioscience's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Twist Bioscience Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Twist Bioscience's Days Payable distribution charts can be found below:
* The bar in red indicates where Twist Bioscience's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Twist Bioscience's Days Payable for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Twist Bioscience (MIL:1TWST) has a Days Payable of 25.84 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Twist Bioscience and its competitors. This is 41% below median its historical median of 44.01. Over the past decade, Twist Bioscience's Days Payable has ranged from 12.51 to 90.54. According to the industry distribution chart, Twist Bioscience ranks #162 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 85.3%.
Is Twist Bioscience's Days Payable too high?
Twist Bioscience's current Days Payable of 25.84 is 41% below median its 10-year median of 44.01. Over the past 10 years, this metric has ranged from a low of 12.51 to a high of 90.54. The Medical Diagnostics & Research industry median Days Payable is 64.95. Twist Bioscience's value of 25.84 is 60.2% below this industry median. Based on the distribution chart, Twist Bioscience ranks #162 out of 190 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Twist Bioscience has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Twist Bioscience's Days Payable compare to BLLN and SHC?
According to the Medical Diagnostics & Research industry distribution chart, Twist Bioscience ranks #162 out of 190 companies for Days Payable. This places Twist Bioscience in the lower half of its industry. The industry median Days Payable is 64.95. Twist Bioscience's value of 25.84 is 60.2% below this benchmark. Historically, Twist Bioscience's own Days Payable has ranged from 12.51 to 90.54 over the past decade. While the company's 10-year median is 44.01 vs. the industry median of 64.95, Twist Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.95, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Twist Bioscience's current Days Payable of 25.84 is 60.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Twist Bioscience and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Twist Bioscience's current Days Payable is 25.84, which is 41% below median its own 10-year median of 44.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Twist Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Twist Bioscience (MIL:1TWST) is currently considered Significantly Overvalued. The stock's GF Value™ is €46.60, compared to a current price of €97.44 — trading 109.1% above its estimated fair value. The current Days Payable is 25.84, which is 41% below median its 10-year median of 44.01 and 60.2% below the Medical Diagnostics & Research industry median of 64.95. Twist Bioscience's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Twist Bioscience (MIL:1TWST), the current Days Payable is 25.84 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Twist Bioscience (MIL:1TWST) Overvalued in 2026?
Based on GuruFocus' analysis, Twist Bioscience stock appears to be overvalued.
The current stock price of €97.44 is trading 109.1% above its estimated GF Value™ of €46.60.
GuruFocus considers Twist Bioscience to be Significantly Overvalued.
Key valuation signals for MIL:1TWST:
Days Payable: 25.84 (41% below median its 10-year median of 44.01)
GF Value™: €46.60 vs. price of €97.44 (109.1% above fair value)
Industry Position: 60.2% below the Medical Diagnostics & Research median (#162 of 190)
No single metric tells the full story. See the MIL:1TWST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
47GF Score
Get the complete analysis for MIL:1TWST
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1TWST has been successfully added to your 
